The initial research questions posed by the scientists faced with SARS-CoV-2 outbreaks were focused on documenting the clinical presentation and the characteristics of the spread of the SARS-CoV-2 virus among CYP [1-3], and the optimal ways to diagnose CYP and treat those in need [1,4]. It quickly became apparent that younger age groups have a considerably milder clinical presentation, but also that they can very rarely develop a considerably more serious Multisystem Inflammatory Syndrome in Children (MIS-C) [1]. A special interest arose in how best to protect those particularly vulnerable. In this Editorial, we discuss the development of scientific evidence related to those research questions in children and young people during the first two years of the COVID-19 pandemic, based on the information available until December 1st, 2021.

EARLY RESEARCH ON THE SYMPTOMS AND SPREADING OF THE SARS-COV-2 AMONG CHILDREN AND YOUNG PEOPLE

Zimmermann and Curtis provided one of the earliest overviews of the epidemiology, clinical features, diagnosis and treatment in children [5]. Preliminary insights suggested that children were just as likely as adults to become infected with SARS-CoV-2, but they showed symptoms less frequently, particularly severe ones. Critically, the importance of younger age groups in spreading the virus in the population remained very uncertain [5]. Children also seemed to have gastrointestinal symptoms more often. Experts agreed that the high proportions of asymptomatic or mildly symptomatic infections in children deserved careful attention, as they could be spreading the virus more readily [6,7].

Analysis from the Robert Koch Institute in Germany early in the pandemic, in March and April 2020, demonstrated a relative increase over time in the prevalence of infections among 15-34 age group – particularly 20-24 age group – compared with 35-49 and 10-14 age groups following the introduction of physical distancing measures [8]. Understanding why the same virus causes such different symptoms across the age spectrum presented a unique opportunity to learn about disease-modifying host factors by studying young populations [9-12].

Igor Rudan¹, Davies Adeloye¹, Srinivasa Vittal Katikireddi², Josie Murray³, Colin Simpson⁴, Syed Ahmar Shah⁵, Chris Robertson⁶, Aziz Sheikh⁵; EAVE II collaboration

¹Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, UK
²MRC/CSO Social & Public Health Sciences Unit, Glasgow, UK
³COVID-19 Surveillance Lead, Public Health Scotland, Fife, UK
⁴School of Health, Wellington Faculty of Health, Victoria University of Wellington, New Zealand
⁵Usher Institute, The University of Edinburgh, Edinburgh, UK
⁶Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK and Public Health Scotland, Glasgow, UK

Cite as: Rudan I, Adeloye D, Katikireddi SV, Murray J, Simpson C, Shah SA, Robertson C, Sheikh A; EAVE II collaboration. The COVID-19 pandemic in children and young people during 2020-2021: Learning about clinical presentation, patterns of spread, viral load, diagnosis and treatment. J Glob Health 2021;11:01010.
Further information continued to arrive from all over the world. Media reported on twelve critically or mortally ill children before April 6, 2020 [13]. There was concern in early Chinese studies about vertical mother-to-child transmission, with six early-onset (<7 days) and 3 late-onset neonatal SARS-CoV-2 infections found in the early literature [13]. The new virus was detected in nasopharyngeal swabs of all hospitalized children, in stool samples in 89%, and oropharyngeal swabs in 33%, but not in sera or urine samples [14]. The median duration of viral shedding was 13 days for the nasopharynx, 4 days for the oropharynx, and 43 days for stools [14]. A study of asymptomatic caretaker-child pairs in New York in May and June 2020, identified the rate of asymptomatic COVID-19 of 2.5% in hospitalized children and 7.5% in caretakers [15]. In Pakistan, recovery from COVID-19 in children has been reported as “largely universal”, with less than 2% with severe disease requiring intensive care [16].

Then, larger studies began to appear. The Paediatric Tuberculosis Network European Trials Group (ptbnet) conducted a multinational, multicentre study in 82 health care institutions from 25 European countries. They studied all minors with confirmed SARS-CoV-2 infection in April 2020, during the first wave of the pandemic in Europe, and found 582 cases. The median age was 5.0 years (IQR 0.5-12.0), the sex ratio of 1.15 males per female, 25% had pre-existing medical conditions, 62% were hospitalized, 8% required ICU admission, and 4% mechanical ventilation. Risk factors for requiring ICU admission were being younger than 1 month (OR=5.1), male sex (OR=2.1), pre-existing medical conditions (OR=3.3), and presence of lower respiratory tract infection (OR=10.5). Eventually, four children died, suggesting the case-fatality rate of 0.69% [17].

Across the Atlantic, in the United States, the report by COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) was based on laboratory-confirmed COVID-19-associated hospitalizations in 14 states and covered a period between March and July 2020. They reported on 576 pediatric COVID-19, quoting the cumulative COVID-19-associated hospitalization rate among minors of 8.0 per 100000 population, which was about 20 times less than in adults. The highest rate was observed among children <2 years (24.8/100000). The authors noted that Hispanic and black children had higher rates (16.4 and 10.5 per 100000, respectively) than white children (2.1). A third of hospitalized children were admitted to an ICU, about 6% required mechanical ventilation, and one patient died [18]. In the United States, minors represented 22% of the population but less than 2% of confirmed SARS-CoV-2 cases as of April 2020, with a period seroprevalence of 1% and most seropositive children not suspected of having had COVID-19 [19].

Further research consolidated the estimate that minors comprise 1%-2% of the diagnosed cases, with a median age of 3.3-11.0 years and with a male-to-female ratio of 1.15-1.55. The most common symptoms in children were upper respiratory symptoms (26%-54%), cough (44%-54%), fever (32%-65%), and gastrointestinal symptoms (15%-30%), while between 4%-54% were asymptomatic. Case-fatality rates could be up to 0.7% [20-26]. In four New York hospitals, 28% of patients required critical care, and among them 35% required respiratory support, with 9% needing mechanical ventilation, but all patients survived.

As case series of studied children grew larger, the preliminary report of pediatric COVID-19 from the US Centers for Disease Control (CDC) based on 2572 cases between February and April 2020, showed that 20% received inpatient treatment and 2% required admission to the intensive care unit – in line with early reports from other countries [26]. Larger numbers allowed for some differentiation within the minor age groups. An interesting observation was that the infected children were less likely to have asthma, that children aged 6-13 years were often asymptomatic (39%) and had respiratory symptoms less often (29% - in comparison to 48% in younger children and 60% in adolescents). Furthermore, in comparison to children aged 6-13 years, adolescents were more frequently diagnosed with influenza-like symptoms (61% vs 39%), gastrointestinal symptoms (27% vs 9%), and sensory symptoms (42% vs 9%). Also, their symptoms persisted longer (median duration: 7 vs 4 days). Interestingly, no difference in nasopharyngeal viral load could be detected by age, or even between symptomatic and asymptomatic children [27].

In the first reports, it appeared that transmission from a household member accounted for nearly 75% of infections in children, with an adult member being the first case in the household in two-thirds of family clusters [24]. A further meta-analysis reported that only 3.8% of transmission clusters were identified as having a pediatric index case [28].

A systematic review and meta-analysis of 65 articles representing 1214 children aged 0-4 years with laboratory-confirmed COVID-19 infection showed that about 50% were infants, 53% were male, 43% were asymptomatic and 7% had a severe disease that required intensive-care-unit admission. The study also confirmed vertical transmission, because 3.6% of newborns from COVID-19 infected mothers were COVID-19 positive. Among those 1214 children, one death was recorded [29]. Management using a combination of supportive care, standard practice intensive care management, and anti-inflammatory agents were most likely to lead to recovery, while long-term sequelae of viral exposure remained unknown at this point of the pandemic [30].
The risk for the severe form was the highest in the neonatal age group, among males, children with lower respiratory tract disease, with pre-existing medical conditions and obesity. Vertical transmission from mother to child was confirmed. In mid-2020, the first reports of the very rare multisystem inflammatory syndrome (MIS) appeared in connection with SARS-CoV-2 infection, with fever, involvement of multiple organs and systems and positive laboratory markers of inflammation [20,25]. The percentage of asymptomatic cases vaccinated with BCG was not significantly higher that without BCG vaccination [30.7% vs 46.2%, \( P = 0.203 \)]. Initial symptoms were not related to the immunized influenza vaccine (\( P = 0.267 \)) [31]. Seropositive young adults had about one-fifth the risk of subsequent infection compared with seronegative individuals. Although antibodies induced by initial infection were largely protective, they did not guarantee effective SARS-CoV-2 neutralisation activity or immunity against subsequent infection [32,33].

An interesting question was the duration of humoral immune response in children. Some authors detected specific IgGs 6 months after infection in children who were either asymptomatic or had mild symptoms [34]. However, other studies suggested waning of antibody responses in children 4-6 after SARS-CoV-2 infection, while parents had somewhat higher levels, but still waning [35,36].

Early studies suggested that vertical transmission of SARS-CoV-2 was rare, but it seemed associated with an increased risk of premature birth and higher neonatal morbidity and mortality. Maternal infection should not affect either the mode of delivery or cord clamping routines and rooming-in and breastfeeding were not counter-indicated. Antibodies against SARS-CoV-2 seemed to cross the placenta and could also be found in breast milk, thus providing some protection for the newborn [37]. Like adults, children could also have long-term complications of COVID-19, which may include neurological and cardiac morbidity [38].

Epidemiological studies showed that outbreaks associated with child care facilities, defined as "two or more laboratory-confirmed and epidemiologically linked cases at a facility within 14 days", occurred in about 6% of the facilities, but accounted for about 50% of total cases [39]. Meanwhile, between March and April 2020, a rapid decline in cases of acute respiratory infections was epidemiologically observed across the USA, especially in the proportion of RSV and influenza, which was attributed to community mitigation measures against SARS-CoV-2 [40]. On the other hand, concerns over the indirect effects of the anti-epidemic measures on child health included psychiatric morbidities, loss of education, unhealthy lifestyle and increased neglect of children [20].

Based on the information from the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET) in 2021, CDC examined COVID-19-associated hospitalizations among adolescents aged 12-17 years. Among 204 adolescents who were likely hospitalized primarily for COVID-19 from January to March 2021, 31% were admitted to an ICU and 5% required invasive mechanical ventilation, with no deaths occurring. Among 204 adolescents who were likely hospitalized primarily for COVID-19 from January to March 2021, 31% were admitted to an ICU and 5% required invasive mechanical ventilation, with no deaths occurring. From March to April 2021, weekly adolescent hospitalization rates fluctuated from 2.1 per 100,000 in early January 2021, then 0.6 in mid-March, and then 1.3 in April. Cumulative COVID-19-associated hospitalization rates in the extended period between October 2020 and April 2021 were 2.5-3 times higher than were influenza-associated hospitalization rates in the preceding three influenza seasons (2017-2020), based on the Influenza Hospitalization Surveillance Network (FluSurv-NET) [41,42].

An umbrella review covering published systematic reviews from December 2019 to April 2021 studied epidemiological, clinical and biomarker profiles of pediatric patients infected with COVID-19. A total of 38 systematic reviews covered 1145 studies and 334,398 children and adolescents. The review showed that patients with comorbidity were at higher risk, with 21% (95% CI: 17.8%-24.7%) of the patients being asymptomatic, and that mortality rate was 0.12% (95% CI: 0.036%-0.246%). It confirmed that fever (in 48%-64%) and cough (in 35%-56%) were common symptoms, and ground-glass opacities (in 27%-62%) were the most frequent radiographic observation. Increased C-reactive protein (CRP) level was found in 14%-54%, lactate dehydrogenase (LDH) in 12%-50% and D-dimer in 0%-67% [43].

In low and middle-income countries (LMICs), children and young people contribute to a higher proportion of the total population. Therefore, the features of COVID-19 among CYP are very relevant for society. They are also considerably more likely to suffer from HIV or malnutrition. The pandemic will worsen their situation because it will divert resources from child health to address the needs of the affected adults. Lack of sanitation, running water, universally accessible masks and crowding will likely facilitate the transmission of SARS-CoV-2 in this population. It is expected that this will increase poverty, disrupt schooling, prevent access to school feeding and health facilities, and interrupt other important vaccinations [44].

By the end of 2020, SARS-CoV-2 was identified on antemortem or post-mortem sampling, and eighteen (90%) of 20 deaths with SARS-CoV-2 infection were in children younger than 1 year. Lung histopathologic features included diffuse alveolar damage in 55%, type 2 pneumocyte proliferation in 55% and hyaline membrane...
formation in 36%, with the culture-confirmed invasive bacterial disease also evident in 55% of COVID-19 attributed deaths. Interestingly, COVID-19 was in the causal pathway of 11% of all childhood deaths under surveillance [45,46].

Studies conducted throughout 2021 brought further understanding to a spectrum of clinical symptoms and patterns of spread of the COVID-19 in children [47-70]. A study in Belgium found anti-SARS-CoV-2 antibodies in 4.4% of children in the low transmission region and 14.4% of children in the high transmission region. A higher risk of seropositivity was associated with a contact with a confirmed case (RR = 2.9), participation in extracurricular activities (RR = 5.6), or a caregiver health care worker who had contact with COVID-19 patients (RR = 2.2). The study showed that, when SARS-CoV2 circulation in the community is high, this will be reflected in the pediatric population with similar infection rates [47]. A clear association was established between the duration of the COVID-19 symptoms in children and the generated IgG units [48].

Big studies in the USA, from the COVID-NET collaboration in 14 US states, calculated that between March 1, 2020, and August 14, 2021, the cumulative incidence of COVID-19-associated hospitalizations was 49.7 per 100,000 children and adolescents. Furthermore, during June 20-July 31, 2021, the hospitalization rate among unvaccinated adolescents (aged 12-17 years) was 10.1 times higher than that among fully vaccinated adolescents [49]. Importantly, the prevalence of severe disease after the Delta variant became predominant (June 20-July 31, 2021) was similar to the same indicator earlier in the pandemic (March 1, 2020-June 19, 2021) [49]. Analyses from the CDC focused on the new COVID-19 cases, emergency department visits and hospital admissions among persons aged 0-17 years between August 1, 2020-August 27, 2021 (the Delta variant period) showed that COVID-19-related emergency department visits and hospital admissions in the states with the lowest vaccination coverage were 3.4 and 3.7 times that in the states with the highest vaccination coverage, respectively. In the hospitals, the proportion of COVID-19 patients aged 0-17 years admitted to an ICU ranged from 10%-25% during August 2020-June 2021 [50]. Another study in the USA involved 45 US children’s hospitals with 4063 hospitalizations [57]. The severity of COVID-19 was moderate in 79%, severe in 11%, and very severe in 9%. Factors associated with hospitalization included obesity and diabetes (adjusted OR = 10.4), asthma (OR = 1.4), cardiovascular disease (OR = 5.1), immunocompromised condition (OR = 9.9), pulmonary disease (OR = 3.5), pancreatitis (OR = 8.9), and neurologic disease (OR = 3.2). Greater severity of symptoms was also associated with Black or other non-White race and age greater than 4 years. Further US-based studies confirmed the important role of obesity and a past medical history of diabetes as significantly more prevalent in hospitalized children, while the history of asthma or lower socioeconomic status did not reach statistical significance [66]. Among children aged ≥12 years in Oregon and Washington states in the USA, the incidence of SARS-CoV-2 infection in the July-September 2021 period was 30.1 per 1000 unvaccinated persons and 8.7 per 1000 vaccinated [67].

In Brazil, during the first weeks of the pandemic, the number of COVID-19 hospitalisations increased in older adults but decreased in younger adults. However, from 2021, the number of hospitalisations changed. Hospitalisations of younger adults increased to reach 44.9%, while hospitalisations of older adults decreased to reach 17.3% [51].

In Canada, the Canadian Paediatric Surveillance Program COVID-19 Study Team reported on 264 hospital admissions involving children with SARS-CoV-2 infection, where 57% of admissions were related to COVID-19 and 38% were incidental infections. Infants (37%) and adolescents (30%) represented most cases. Among COVID-19-related hospitalizations, 35% had the critical disease, and 28% of them required respiratory or hemodynamic support, with 39% having at least one underlying comorbidity [53-55]. Another Canadian study included 1632 participants providing samples from 30 day cares, 22 primary schools, and 11 secondary schools. The mean seroprevalence was 5.8%, but it increased from 3.2% in the fall of 2020 to 8.4% in the spring of 2021. Of the 95 children with SARS-CoV-2 antibodies, 82% were not tested or tested negative with reverse transcription-polymerase chain reaction (RT-PCR) testing, and all experienced mild (52%) or no symptoms (48%). The children of parents who self-identified as belonging to a racial and ethnic minority group were about twice as likely to be seropositive [69].

In Switzerland, the Swiss Paediatric Surveillance Unit collected data from children <18 years with confirmed SARS-CoV-2 infection based on the input from all 33 paediatric hospitals. The analysis included 678 children with a median age of 12.2 years, 46.6% female and 15.6% with comorbidities. Eventually, 126 children were hospitalised and 16 required ICU admission. Comorbidities seemed to be the only factor associated with hospital admission in a multivariable regression analysis (OR = 3.2). Hospitalised children more often presented with fever (76.2%) and rash (12.8%). Complications were reported in 28 children, and cardiovascular complications were the most frequent – in 12 children. In total, three deaths were reported [70].
In Australia, a national prospective study was conducted to characterise SARS-CoV-2 infections among children presenting to paediatric hospitals. There were 381 children with COVID-19, 53% were male and 1.3% had multisystem inflammatory syndromes. Nearly 20% of children had comorbidities. All children recovered and most had mild disease [63]. However, in England, the situation was very different: of about 12 million CYP who lived in England in 2020, there were 3105 deaths, and 61 of those who died were positive for SARS-CoV-2. Among them, 25 were due to SARS-CoV-2 infection, giving a mortality rate of two deaths per million children. It is recorded that 22 deaths were due to COVID-19, while 3 were attributed to the pediatric inflammatory multisystem syndrome. In comparison to all CYP deaths, children older than 10 years, Asian and Black ethnic backgrounds and comorbidities were over-represented [64]. In Russia, a rare case of stillbirth due to antenatal asphyxia with aspiration pneumonia was described. The child was positive for SARS-CoV-2 and immunohistochemical investigations showed viral infection and cellular changes in several organs, including the pancreas, brain, spleen, and adrenals [65].

To improve understanding of the patterns of spread, a study in Utah and New York involved surveillance of 1236 participants in 310 households, with 14% aged 0-4 years, 25% aged 5-11 years, 13% aged 12-17 years, and 47% aged 18 years or older. The incidence rate of SARS-CoV-2 infection in Utah was 3.8 per 1000 person-weeks, and in New York 7.7 per 1000 person-weeks, and the rates were similar by age groups of children. However, the asymptomatic fraction was the highest in 0-4 years (52%), then 5-11 years (50%), 12-17 years (45%), and 18+ years (12%). In households with cases of infections, the mean risk of SARS-CoV-2 infection among all other members was 52% (range: 11%-100%). The study showed that children had similar incidence rates of SARS-CoV-2 infection compared with adults, but a larger proportion of infections among children were asymptomatic [58,59,61].

In Japan, researchers tried to estimate the secondary transmission rate at schools using the results of a real-time reverse transcription-polymerase chain reaction (RT-PCR) screening test. They evaluated 1924 students from 52 schools or preschools. The authors estimated the probability of transmission after each contact at school as approximately 0.5% per contact with the infection prevention measures at schools in Japan, which included hand hygiene, physical distancing, wearing masks, and effective ventilation. Assuming that all children are capable of carrying the infection, contact between an infected case and 20-30 students per day at schools would lead to more than 1 secondary case during the ten days of the infectious period [68].

Some studies tried to understand better the immune response in children, as compared to adults. In children, when compared with adults, the antiviral response resolves faster - within a week of symptoms. Monocytes and dendritic cells are less activated, while genes associated with B cell activation appear earlier in children, but these differences do not have major effects on specific antibody responses [56]. A study in Germany showed that about 60% of antibody-positive children showed very high levels of antibodies against N-protein and the S-protein, with 86% developing a sufficient neutralizing activity regardless of age and sex. Approximately 30% of PCR-positive children did not show seroconversion. Symptoms of SARS-CoV-2 infections are unspecific in children, with antibody responses either being very strong in many children or not detectable at all [60]. In the United States, among the 1038 children, researchers found an anti-SARS-CoV-2 antibody positivity rate of 8.5%, but as many as 66% of seropositive children had no symptoms of COVID-19. Seropositivity in children was much higher than that in adults in the same region at a similar time [62].

**VIRAL LOAD IN CHILDREN AND YOUNG PEOPLE**

In the early stages of the pandemic, viral load (VL) estimates for children were missing. It initially seemed the secondary attack rate was lower if the infector was a child, but this needed to be confirmed through larger studies [71]. In one of the first attempts, viral load at diagnosis was compared between 53 children and 352 adults with COVID-19 at some point during the first five days after the first symptoms appeared. The study found no significant differences in SARS-CoV-2 RNA loads between children and adults [72]. At the same time, another report could not prove SARS-CoV-2 carriage in children attending daycare centres during the initial weeks of the epidemic in Belgium [73]. Uncertainty over the viral load and secondary attack rate in children prompted views that dramatic public health measures like school closures were not evidence-based, leading to a heated debate over the issue [74-77].

Further study based on 110 children with COVID-19 with a median age of 10 years showed that age, which ranged widely - from 2 weeks to 21 years - did not seem to affect SARS-CoV-2 viral load [78-82]. All children appeared to be most infectious within the first five days of the onset of symptoms, while the severity of the disease did not seem to correlate well with increased viral loads [78]. Also, the severe disease did not correlate
with increased viral loads. SARS-CoV-2 sequences detected among children were representative of those in the community, with novel variants seen in the laboratory. It has been shown that both symptomatic and asymptomatic children can carry high quantities of life, replicating SARS-CoV-2, which can create a potential reservoir for SARS-CoV-2 transmission and evolution of genetic variants [82]. Unsurprisingly, studies based on the virological profiling of asymptomatic children suggested that they do have lower viral loads, as well as faster virus clearance, with no significant age-related differences [79,80]. Among the affected children, activated and senescent cells were higher in adults than in children, while regulatory cells were higher in children. In adults, higher immune activation persisted after 6 months of infection, while children maintained high levels of regulatory cells. The studies showed that adults displayed higher immune activation and lower production of anti-SARS-CoV-2 neutralizing antibodies than children, and this difference in immune response was not related to different viral loads [83]. Laboratory analyses based on saliva samples demonstrated the heterogeneity of the SARS-CoV-2 antibody response in children and showed the additional value of saliva antibody detection [84].

More advanced studies resorted to the use of “systems serology” to examine functional phagocyte and complement-activating IgG response to SARS-CoV-2. In children, these were similar to the acute responses generated in adults with mild disease. However, IgA and neutrophil responses were significantly expanded in adults who suffered from more severe forms of the COVID-19. This prompted interest in the serological signature of those rare children who develop MIS-C. They would typically maintain highly inflammatory monocyte-activating SARS-CoV-2 IgG antibodies. Their IgG levels distinguished them from acute disease in children and were more similar to those in convalescent adults. These findings suggested that the interplay of IgG and IgA may be indicative of disease severity and unexpected complications in children [81].

**DIAGNOSIS AND TESTING**

Among children and young people, COVID-19 is diagnosed the same way as in adults. A specimen obtained from the upper respiratory tract is tested for nucleic acid amplification (NAAT) using reverse transcriptase viral polymerase chain reaction (RT-PCR). In addition to confirming the presence of viral genetic material, hospitalized patients will typically have leukopenia and increased levels of inflammatory markers. Chest x-ray findings can be very variable. Computed tomography scans of the chest will occasionally show “ground-glass opacities” that are similar to adults, but non-specific findings are also common [85]. Symptoms in children will be milder, including cough, fever, sore throat, myalgia sneezing, and fatigue, but adults will be more severely affected. Lymphopenia may or may not be present and it seems to be less pronounced than in adults [85,86].

It seems that over a third of hospitalized children show redetectable positivity. This is more common among children from family cluster infections, and also those who had relatively higher white blood cell (WBC) count and longer plasma prothrombin time (PT), while age and gender were not associated with this feature [87].

SARS-CoV-2 antigen-specific Fcγ receptor binding accurately distinguishes COVID-19 patients from healthy individuals, suggesting that SARS-CoV-2 infection induces qualitative changes to antibody Fc, enhancing Fcγ receptor engagement. Higher cross-reactive SARS-CoV-2 IgA and IgG are observed in healthy elderly, while healthy children display elevated SARS-CoV-2 IgM. This finding suggests that children have fewer hCoV exposures, resulting in less experienced, but more polyreactive humoral immunity. Age-dependent analysis of COVID-19 patients confirms elevated class-switched antibodies in the elderly, while children have stronger Fc responses which are functionally different [88,89].

**HYPOTHESES ON THE REASONS FOR Milder CLINICAL PRESENTATION IN CHILDREN AND YOUNG PEOPLE**

The striking early observation in the pandemic – ie, that younger age groups have a considerably milder clinical presentation - has sparked interest from several authors [90-96]. It was clear that it could be suggesting something important about the role of the host in the severity of the disease. Hospitalized children’s case fatality rate in the early stage of the pandemic was estimated to be below 1%, compared with 27% across all ages [90]. The first theories suggested that the expression of angiotensin-converting enzyme 2 (ACE2), a receptor for the SARS-CoV-2 spike protein, in upper airways may be very low in children. Then, it can increase with age. It was also noted that higher expression of ACE2 was associated with SARS-CoV-2 genomic RNA positivity in swabs from upper airways in symptomatic children, but it did not correspond as well with viral load [90]. Another theory suggested that children simply do not develop a maladaptive immune response that leads to acute respiratory distress syndrome (ARDS) in older patients [90].
Soon, further ideas followed. Some authors proposed that children have more frequent contact with seasonal coronaviruses than adults, so they may harbour antibodies that provide cross-reactivity with or without clearance with other viruses [91]. Another view of the role of ACE2 was that its expression in young people may be increased so that it facilitates SARS-CoV-2 infection in children. However, at the same time, it limits inflammation and reduces the risk of severe disease [91]. There were speculations that recent vaccinations against other viruses may - in some yet unrecognised way - limit the pathogenicity of SARS-CoV-2 in children [93]. The sixth theory, then, suggested that children may have a more diverse memory T-cell repertoire [91].

Further authors speculated that immunosenescence in older people makes them more likely to suffer a more threatening clinical presentation [92], or that a more frequent co-infection with other viruses may provide protection to children [92]. Some authors suggested that lifetime exposure to smoking may play a role [92].

The discussion on this issue then moved from a speculative hypothesis to exploring some measurable indicators that could provide clues. Several authors compared biomarkers in children and adults to study the possible role of the renin-angiotensin system, indicators of the immune response, levels of interleukin (IL)-6, IL-10, myeloperoxidase, P-selectin, intracellular adhesion molecule-1, the role of lymphocytes and the detection of lung infiltrations [93]. It was also speculated that high-titer immunoglobulin-G antibodies against respiratory syncytial virus and mycoplasma pneumonia may carry out cross-protection against SARS-CoV-2 infection in children [93].

Some authors focused on the age-related increase in endothelial damage and changes in clotting function [94]. This further increased interest in measuring density, affinity and distribution of ACE2 receptors, but also transmembrane serine protease 2 [94]. A hypothesis on the role of pre-existing coronavirus antibodies expanded to also study antibody-dependent enhancement and the role of T cells [94]. Theories on the role of immunosenescence further focused on “inflammaging” and a possible role of chronic cytomegalovirus infection [94]. It also became clear that comorbidities, present among older adults, but not children, may be associated with severe COVID-19 in some way. The community interested in the role of vitamin D levels in pathophysiology started looking at its possible contribution [94]. Further hypotheses on why children may be protected included differences in innate and adaptive immunity between children and adults, differences in microbiota, higher levels of melatonin, protective off-target effects of live vaccines, and possibly lower intensity of exposure to SARS-CoV-2 [94].

Interestingly, children with asthma did not appear to be more affected by COVID-19 [95], raising the question of whether atopy may be protective and why, although this issue may not be settled yet. Some theories suggested the possible role of lower IFN-α production, the protective role of eosinophils in the airway, antiviral and immunomodulatory proprieties of inhaled steroids, and allergic sensitization being inversely related to ACE2 expression [95]. The issue is further complicated by the notion that obesity – which is a recognised risk factor in adults – does not seem to associate with increased risk in children with asthma-obesity phenotype [95]. The main concern in children is progression to acute respiratory distress syndrome, which is still sometimes possible – but where “the cytokine storm” that endangers adults is considerably less likely and the mortality is low [96].

MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C)

After establishing that most cases in children and young people are asymptomatic or mild, the research soon focused on the rare exception – the severe form of the disease in children, termed MIS-C [97-111]. It presents initially with fever, feeling very unwell, diarrhoea, shock and it affects two or more organ systems. There may also be the variable presence of rash, conjunctivitis, extremity oedema, and changes of the mucous membrane. In some cases, a progression to multi-organ failure can occur [97,100].

Laboratory tests show elevated markers of inflammation and positivity for SARS-CoV-2 infection. Paediatricians soon realised that MIS-C has similarities with some other conditions in this age group, such as Kawasaki Disease (KD), toxic shock syndrome, and secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome. The pathogenesis of COVID-19-associated MIS-C likely involves post-infectious immune dysregulation and its treatment requires pediatric intensive care because rapid clinical deterioration can occur among those affected [97,101,106,107,109]. Since the beginning of the pandemic, there was a need to develop a clear case definition and treatment protocol for MIS-C [98,111].

Several groups conducted studies to characterise MIS-C in COVID-19-affected children. Early research found high titers of SARS-CoV-2 RBD IgG antibodies, nucleocapsid protein antibodies and neutralizing antibodies. Children with MIS-C also have detectable RBD immunoglobulin M antibodies, indicating recent infection with...
SARS-CoV-2. RBD IgG titers correlated well with the erythrocyte sedimentation rate, length of stay in the hospital and ICU [99]. As clinical features initially seem compatible with incomplete KD and Toxic Shock Syndrome (TSS) thought to be related to a cytokine storm, cytokine studies in sera showed increased IL1RA levels (by about 10-20 times), while IL-6 was increased in about half of those affected [104].

Further research managed to assemble a cohort of 539 cases with MIS-C who were then compared with 577 children with COVID-19. MIS-C was more frequent in 6-12 age group. The cases of MIS-C were more likely to show cardiorespiratory involvement and higher neutrophil to lymphocyte ratio, higher C-reactive protein level and lower platelet count. About three in four children with MIS-C were admitted to the ICU, in comparison to less than a half in those with COVID-19. The case-fatality rate among hospitalized children was 1.9% among those who developed MIS-C and 1.4% among those with COVID-19 [105]. Moreover, children with MIS-C can exhibit gastrointestinal symptoms, coagulopathy, shock and an atypical KD syndrome with fever, mucocutaneous lesions, lymphadenopathy and/or cardiovascular events [108].

It is known that certain HLA subtypes are associated with KD. Genetic studies implicated HLA-B*46:01 as the risk allele of severe COVID-19 infection, while blood group O is a protective factor. It is hypothesized that MIS-C could be mediated by a genetic variant of HLA, FcγR, and/or antibody-dependent enhancement (ADE), leading to hyperinflammation associated with T helper 17 (Th17)/Treg imbalance and increased levels of Th17/Th1 mediators - including IL-6, IL-10, IP-10, IFNγ and IL-17A. At the same time, Treg-signalling molecules, FoxP3 and TGF-β are decreased. Intravenous immunoglobulin (IVIG) – alone or combined with corticosteroids - is the standard treatment for KD, KDSS, and MIS-C [108]. Children with MIS-C are significantly more likely to develop pleural effusions on chest radiograph (in 82%) and a lower zone predominance of pulmonary opacifications (in 100%). On abdominal imaging, they have signs of intra-abdominal inflammatory changes [103].

The diagnosis of MIS-C cases will likely become even more challenging after vaccine uptake or natural acquired immunity [110,112]. It is unclear why the disease progresses to severe MIS-C in some children, although they have anti-SARS-CoV-2 antibodies. One explanation could be the presence of the antibody-dependent enhancement (ADE) as a mechanism underlying the clinical syndrome. If true, this should be considered in vaccine development against SARS-CoV-2 [100]. Further studies implied the pathogenesis consistent with the postinfectious inflammatory syndrome, characterised by an elevation in all cytokines and markers of recent T-cell activation (sIL-2R) despite a strong and specific humoral response to SARS-CoV-2 [102,113].

**EARLY RESEARCH ON TREATMENT EFFECTS**

Although most SARS-CoV-2 infections in children were either asymptomatic or mild, the emergence of occasional hospitalizations, the presence of particularly vulnerable children in the population and the rare cases of Multisystem Inflammatory Syndrome prompted research into treatments [17,85,114-119]. The presence of pneumonia, severe disease or critical illness would require hospital admission and aggressive management for acute lung injury, shock and/or multiorgan dysfunction. The early opinion from expert panels suggested that early intubation should be preferred over non-invasive ventilation, or overheated, humidified, high flow nasal cannula oxygen in children. This early advice was based on concern that the latter two approaches may generate aerosols, which would increase the risk of infection in hospital staff.

Later, severe COVID-19 in children was defined as a “supplemental oxygen requirement without the need for non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)”. Remdesivir for 5 days was the first medication suggested for treating children, but preferably as part of a clinical trial, to assist better understanding of its effectiveness in younger age groups. Remdesivir was also suggested for critically ill children who required either invasive or noninvasive mechanical ventilation or ECMO. Hydroxychloroquine or Lopinavir-Ritonavir, or other protease inhibitors, were not recommended for COVID-19 in children as they didn’t show effectiveness in clinical trials in adults [115]. Early antivirals that were being used among rare children with a particularly severe course of the disease at the beginning of the pandemic included hydroxychloroquine, remdesivir, lopinavir-ritonavir and oseltamivir. Immunomodulation was also attempted using dexamethasone and other corticosteroids, intravenous immunoglobulin, tocilizumab, anakinra and siltuximab [17,119]. Treatments with azithromycin and convalescent plasma were also attempted [114].

Oxygen therapy was typically administered to hypoxic children, with saturation <92%. Similar to adults, oxygenation was maintained through the use of a high flow nasal cannula, CPAP, or ventilatory support, using low tidal volumes (5-6 cc/kg), high positive expiratory pressure, adequate sedation, paralysis, and prone positioning [114]. However, ventilation management interim guidance in the early stage of the pandemic had to rely on evidence-based guidelines in non-COVID ARDS. Decisions needed to be made be-
tween noninvasive positive pressure ventilation and high-flow nasal cannula; and also, between high and lower positive end-expiratory pressure strategies related to lung compliance. Management of acute respiratory failure required individualized titration of noninvasive and invasive ventilation, closely considering preserved pulmonary compliance [118].

In November 2020, the US Food and Drug Administration (FDA) provided Emergency Use Authorizations (EUA) for two new virus-neutralizing monoclonal antibody therapies - bamlanivimab and REGN-COV2 (casirivimab plus imdevimab). These drugs were authorised for the treatment of mild to moderate COVID-19 in adolescents and adults in precisely defined high-risk groups, based on recommendations from a panel of experts from 29 North American institutions. They noted that, while there was limited evidence of modest benefit in adults, there was no strong evidence for the safety and efficacy of monoclonal antibody treatment of COVID-19 in children or adolescents. Based on evidence that was available on December 20, 2020, the panel suggested against routine administration of monoclonal antibody therapy (bamlanivimab, or casirivimab and imdevimab) for treatment of COVID-19 in children or adolescents, including those at high risk of progression to hospitalization or severe disease [116]. At that time, it was expected that the approval of vaccines by the FDA under emergency use authorization for children and adolescents will be a better way to protect those most vulnerable [85,117].

**STUDY OF COVID-19 IN PARTICULARLY VULNERABLE CHILDREN**

After the symptoms in children were better understood and the treatment options explored for the MIS-C syndrome, the first vaccines to prevent COVID-19 became licensed for adults. This immediately led to an interest in whether particularly vulnerable children could also be vaccinated, and what is their risk of disease and treatment options. A study of nine patients with congenital heart disease showed that two of them died from COVID-19, which led to severe types of congenital heart disease (CHD), worsened arterial blood gases, severe clinical symptoms, a higher mean level of partial thromboplastin time and C-reactive protein [120]. This indicated that any risk of vaccinating children with CHD would likely be much smaller than the risk that COVID-19 posed. A study of 1490 immunocompromised children, defined as those requiring an annual influenza vaccination due to their underlying condition or medication, showed that their shielding worked very well during the pandemic in the UK because no one tested positive for SARS-CoV-2 [121]. In France, the Leukemia Committee of the French Society for the fight against Cancers and Leukemias in Children and Adolescents (SFCE) proposed specific recommendations, in absence of understanding of the risk that COVID-19 poses in these children that would emerge from clinical studies [122]. The paucity of data was also highlighted for pediatric solid organ transplant (SOT) recipients, with uncertainty over both the SARS-CoV-2 infection and the vaccination in terms of safety, immunogenicity, and vaccine efficacy. It was stressed that trials that would include pediatric SOT recipients are much needed and that some are already under way to fill this knowledge gap [123]. In Italy, paediatric oncology units reported on a cohort of 89 adolescent and young adult patients among whom 80 agreed to vaccination. The nine who refused said that they feared side effects, did not believe in the pandemic or did not have trust in the scientific community. Still, the rate of vaccine uptake was higher than in the Italian general population [124]. It was also highlighted that vaccination of children with developmental disabilities should be carefully considered [125].

In a French paediatric oncology institution, a study showed that patients with cancer should be expected to have a severe or critical episode in about 20% of those infected. The study retrospectively evaluated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults (AYA) with a solid tumour, aged 16 or over, who were under treatment for a solid tumour or within 6 months after treatment. They received two administrations of the vaccine 3 weeks apart. Of 23 patients with solid tumours who were offered vaccination, nine refused. Vaccines were well tolerated, with five patients having no side effects after the first injection and four with no side effects after the second injection. The main local reactivity symptoms were mild pain at the site of injection and fatigue. Seven of ten patients had positive serology before the second injection, and four with no side effects after the second injection. The main local reactivity symptoms were mild pain at the site of injection and fatigue. Seven of ten patients had positive serology before the second injection, and four with no side effects after the second injection. The main local reactivity symptoms were mild pain at the site of injection and fatigue. Seven of ten patients had positive serology before the second injection, and four with no side effects after the second injection. Furthermore, all patients with seroconversion had positive COVID-19 neutralisation test and no patient developed COVID-19 [126]. These findings suggest a good safety profile and good efficacy of the BNT162B2 vaccine in people aged 16 years or over with solid tumours [126].

The BNT162b2 COVID-19 mRNA vaccine stimulated higher positive antibody responses in adolescents and young adults who were kidney transplant recipients. Importantly, antibody titers after vaccination were significantly lower than after COVID-19 infection, suggesting that a longer time may be required to mount appropriate humoral immunity to vaccination in KTR [127].
Some authors suggested that vaccines should be considered for implementation at child and adolescent psychiatric hospitals [128]. Others critically reviewed pre-and post-marketing evidence on the potential benefits and risks of marketed COVID-19 vaccines in special cohorts that included immunocompromised children, those with predispositions to allergies, children with other comorbidities [129,130], and those with Down syndrome [131]. It was shown that hospitalised minors with Down syndrome had a higher incidence of respiratory symptoms, fever, and several medical complications from COVID-19 than control patients [131]. Significant risk factors for their hospitalisation were older age, obesity, and epilepsy, and they were generally more prone to severe clinical presentation. Mortality rates were low in all paediatric COVID-19 patients, contrasting with previous findings in adults with Down syndrome who had higher mortality [131]. Among parents of children with an autism spectrum disorder in Southern California, approximately 35% intended to vaccinate their child [132].

Vaccine acceptability was also studied among caregivers of childhood cancer survivors. As many as 21% of caregivers expressed hesitancy to vaccinate themselves and 29% expressed hesitancy to vaccinate their children with cancer. Caregivers who expressed confidence in their federal government’s response to COVID-19 were six times more likely to express willingness to get vaccinated themselves and three times more likely to vaccinate their child with cancer. This research highlighted the need for COVID-19 vaccination education and outreach [133].

Researchers have also studied antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy. They observed attenuated antibody responses to BNT162b2 in children on the treatment in combination with an immunomodulator, but in most patients antibody responses were still acceptable and comparable with adults. These findings highlighted the importance of booster doses to achieve complete protection in vulnerable patients, prompting future investigations to determine the duration of protection by the immune response [134]. Another similar group of especially vulnerable patients are adolescents with juvenile idiopathic arthritis treated with TNF inhibitors. The research showed that mRNA vaccines develop satisfactory immunogenicity at 1 and 3 months post immunisation. The vaccine assures an adequate humoral response against SARS-CoV-2 [135].

CONCLUSION

Research to characterise SARS-CoV-2 infection and COVID-19 in children and young people evolved very rapidly during 2020 and 2021. The early research was focused on understanding the symptoms and spreading of the SARS-CoV-2 among pre-school and school-aged minors. Then, information on viral load in children emerged, leading to optimization of diagnosis and testing in this age group. Given that minors had milder symptoms than adults, several hypotheses were proposed to explain this observation, but the debate is still ongoing. In very rare instances, children would develop a MIS-C. Clinical and biochemical features of this condition were gradually documented, and treatment options tested. The effectiveness of treatment using different antiviral, immunomodulatory or supportive therapies, including assisted respiration and ECMO, was examined and treatment guidelines developed. Then, global research efforts focused on protecting particularly vulnerable children, especially after the first vaccines were licensed for the adult population. This gave rise to a complex discussion on an opportunity for vaccinating children and young people to prevent the disease in this age group.

Acknowledgements: This paper is part of the EAVE II collaboration’s research output on COVID-19 pandemic.

Funding: EAVE II is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE - The Health Data Research Hub for Respiratory Health [MC_PC_19004], which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support has been provided through Public Health Scotland and Scottish Government DG Health and Social Care. SVK acknowledges funding from a NRS Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC_UU_00022/2) and the Scottish Government Chief Scientist Office (SPHSU17).

Authorship contributions: IR conceptualized and drafted the manuscript. Other authors provided important comments, contributed to the final manuscript and checked for important intellectual content.

Competing interests: AS and CR are members of the Scottish Government’s CMO COVID-19 Advisory Group. IR is a member of the Croatian Government’s Scientific Committee on COVID-19 and co-Editor-in-Chief of the Journal of Global Health. AS and CR are members of NERVTAG’s risk stratification subgroup. CR is a member of SPI-M. AS is a member of AstraZeneca’s Thrombotic Thrombocytopenic Advisory Group and the Scottish Government’s Standing Committee on Pandemics. SVK was co-chair of the Scottish Government’s Expert Reference Group on Ethnicity and COVID-19 and a member of the Scientific Advisory Group on Emergencies (SAGE) subgroup on ethnicity. All roles are unremunerated. All other co-authors report no conflict of interests.
REFERENCES

1 Ward JL, Harwood R, Smith C, Kenny S, Clark M, Davis PJ, et al. Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS- Ts in England during the first pandemic year. Nat Med. 2021; Epub ahead of print. Medline:34931076 doi:10.1038/s41591-021-01627-9

2 Cruz AT, Zeichner SL. COVID-19 in Children: Initial Characterization of the Pediatric Disease. Pediatrics. 2020;145:e20200834. Medline:32179659 doi:10.1542/peds.2020-0834

3 Kelvin AA, Halperin S. COVID-19 in children: the link in the transmission chain. Lancet Infect Dis. 2020;20:633-4. Medline:32220651 doi:10.1016/S1473-3099(20)30236-X

4 Balasubramanian S, Rao NM, Goenka A, Roderick M, Ramanan AV. Coronavirus Disease 2019 (COVID-19) in Children - What We Know So Far and What We Do Not. Indian Pediatr. 2020;57:435-42. Medline:32273490 doi:10.1007/s13312-020-1819-5

5 Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. Pediatr Infect Dis J. 2020;39:355-68. Medline:32310621 doi:10.1097/INF.0000000000002660

6 Lu X, Xiang Y, Du H, Wing-Kin Wong G. SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic. Pediatr Allergy Immunol. 2020;31:449-53. Medline:32330332 doi:10.1111/pai.13267

7 Sankar J, Dhochak N, Kabra SK, Lodha R. COVID-19 in Children: Clinical Approach and Management. Indian J Pediatr. 2020;87:433-42. Medline:32338947 doi:10.1007/s12098-020-03292-1

8 Goldstein E, Lipstitch M. Temporal rise in the proportion of younger adults and older adolescents among coronavirus disease (COVID-19) cases following the introduction of physical distancing measures, Germany, March to April 2020. Euro Surveill. 2020;25:2000596. Medline:32372753 doi:10.2807/1560-7917.ES.2020.25.17.2000596

9 Singh T, Heston SM, Langel SN, Blasi M, Hurst JH, Fouda GG, et al. Lessons From COVID-19 in Children: Key Hypotheses to Guide Preventative and Therapeutic Strategies. Clin Infect Dis. 2020;71:2006-13. Medline:32382748 doi:10.1093/cid/ciaa547

10 Mirti SM, Noorbalahsh F, Mohabbi SR, Ghaemi A. Higher prevalence of asymptomatic or mild COVID-19 in children, claims and clues. J Med Virol. 2020;92:2257-9. Medline:32470174 doi:10.1002/jmv.26069

11 Creech CB. It’s True Even in a Pandemic: Children Are Not Merely Little Adults. Clin Infect Dis. 2020;71:2480-1. Medline:32472937 doi:10.1093/cid/ciaa680

12 Bizi N, de Winter JP. COVID-19 in children: patientily and critically evaluate the scientific evidence. Eur J Pediatr. 2020;179:1179-80. Medline:32495145 doi:10.1007/s00431-020-03708-2

13 Jeng MJ. Coronavirus disease 2019 in children: Current status. J Chin Med Assoc. 2020;83:527-33. Medline:32502117 doi:10.1097/CMA.0000000000000323

14 Liu P, Ca J, Jia R, Xia S, Wang X, Cao L, et al. Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19. Emerg Microbes Infect. 2020;9:1254-8. Medline:32515685 doi:10.1080/22221751.2020.1772677

15 Hassoun A, Prasad N, Pugh S, Merced I, Abularrage J, Sharma M. Parental Coronavirus Disease 2019 Testing of Hospitalized Children: Rethinking Infection Control in a Pandemic. J Pediatric Infect Dis Soc. 2020;9:564-5. Medline:32856705 doi:10.1097/pids.ajpid.0000000000001033

16 Khan EA. COVID-19 in children: Epidemiology, presentation, diagnosis and management. J Pak Med Assoc. 2020;70(Suppl 3):S108-S112. Medline:32513889 doi:10.5455/JPMA.25

17 Götzinger F, Santiago-Garcia B, Noguera-Julian A, Lanaspa M, Lancell L, Calo Carducci FI, et al. ptbnet COVID-19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Heal. 2020;4:653-61. Medline:32993339 doi:10.1016/j.lchildheal.2020.03.0172

18 Kim L, Whitaker M, O’Halloran A, Khamhampaiti A, Chai SJ, Reingold A, et al; COVID-NET Surveillance Team. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1081-8. Medline:32790664 doi:10.15585/mmwr.mm6932e3

19 Dingens AS, Crawford KHD, Adler A, Steele SL, Lacombe K, Eguia R, et al. Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. Nat Commun. 2020;11:4378. Medline:32873971 doi:10.1038/s41467-020-18178-1

20 Rabinowicz S, Leshem E, Pessach IM. COVID-19 in the Pediatric Population-Review and Current Evidence. Curr Infect Dis Rep. 2020;22:22. Medline:32825999 doi:10.1007/s11908-020-00739-0

21 Rajapakse N, Dixit D. Human and novel coronavirus infections in children: a review. Paediatr Int Child Health. 2021;41:36-55. Medline:32841499 doi:10.1080/20469047.2020.1781356

22 Perikleous E, Tsalkidis A, Bush A, Parasalakis E. Coronavirus global pandemic: An overview of current findings regarding pediatric patients. Pediatr Pulmonol. 2020;55:3252-67. Medline:32965785 doi:10.1002/ppul.25087

23 Jahangiri M, Nawaz M, Nanji M, Siddiqui MS. Characterizing new cases of COVID-19 infections in children less than 18 years old in Pakistan. J Pak Med Assoc. 2021;71:1919-22. Medline:32993472

24 Maltezou HC, Magaziotou I, Dedoukou X, Eleftheriou E, Raftopoulos V, Michos A, et al. for Greek Study Group on SARS-CoV-2 Infections in Children. Children and Adolescents With SARS-CoV-2 Infection: Epidemiology, Clinical Course and Viral Loads. Pediatr Infect Dis J. 2020;39:e388-92. Medline:33031141 doi:10.1097/INF.0000000000002899

25 Verma S, Lumba R, Dapul HM, Gold-von Simson G, Phoon CK, Lighter JL, et al. Characteristics of Hospitalized Children With SARS-CoV-2 in the New York City Metropolitan Area. Hosp Pediatr. 2021;11:71-8. Medline:33030787 doi:10.1542/hpeds.2020-001917
26. Zimmermann P, Goetzinger F, Ritz N. Additional Concerns Regarding Children With Coronavirus Disease 2019. JAMA Pediatr. 2020;174:1216. Medline:33104175 doi:10.1001/jamapediatrics.2020.2916
27. Hurst JH, Heston SM, Chambers HN, Cunningham HM, Price MJ, Suarez L, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study. Clin Infect Dis. 2021;73:e2875-82. Medline:33141180 doi:10.1093/cid/ciaa1693
28. Zhu Y, Bloxham CJ, Hulme KD, Sinclair JE, Tong ZWM, Steele LE, et al. A Meta-analysis on the Role of Children in Severe Acute Respiratory Syndrome Coronavirus 2 in Household Transmission Clusters. Clin Infect Dis. 2021;72:e1146-53. Medline:32832340 doi:10.1093/cid/ciaa1825
29. Bhuyian MU, Sibthoy E, Hassan MZ, Chan M, Islam MS, Haider N, et al. Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis. Vaccine. 2021;39:667-77. Medline:33342635 doi:10.1016/j.vaccine.2020.11.078
30. Damania R, Moore W, Viamonte HC, Kamat P, Basu RK. Severe acute respiratory syndrome coronavirus 2 infection and critically ill children. Curr Opin Pediatr. 2021;33:286-91. Medline:33938473 doi:10.1097/MOP.0000000000001019
31. Liu S, Yuan C, Lin J, Gao W, Tian D, Cai X, et al. Association between vaccinations and clinical manifestations in children with COVID-19. Transl Pediatr. 2021;10:17-25. Medline:33633933 doi:10.21037/tp-20-225
32. Letizia AG, Ge Y, Vengetti S, Goforth C, Weir DL, Kuzmina NA, et al. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respir Med. 2021;9:712-20. Medline:33865504 doi:10.1016/S2213-2600(21)00158-2
33. Bogunovic D, Merad M. Children and SARS-CoV-2. Cell Host Microbe. 2021;29:1040-2. Medline:34265242 doi:10.1016/j.chom.2021.06.015
34. Toh ZQ, Higgins RA, Do LAH, Rautenbacher K, Mordant FL, Subbarano K, et al. Persistence of SARS-CoV-2-Specific IgG in Children 6 Months After Infection, Australia. Emerg Infect Dis. 2021;27:2233-5. Medline:34016252 doi:10.3201/eid2708.210965
35. Bloise S, Marcellino A, Testa A, Dilillo A, Mallardo S, Isoldi S, et al. Serum IgG levels in children 6 months after SARS-CoV-2 infection and comparison with adults. Eur J Pediatr. 2021;180:3335-42. Medline:34023936 doi:10.1007/s00431-021-04142-w
36. Breuer A, Raphael A, Stern H, Odeh M, Fiszlinski J, Algar N, et al. SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population. Acta Paediatr. 2021;110:3054-62. Medline:34265136 doi:10.1111/apa.16031
37. Shah MD, Saugstad OD. Newborns at risk of Covid-19 - lessons from the last year. J Perinat Med. 2021;49:643-9. Medline:34116585 doi:10.1515/jpm-2021-0258
38. Clark JA, Pathan N. Hide and seek in a pandemic: review of SARS-CoV-2 infection and sequelae in children. Exp Physiol. 2021; Epub ahead of print. Medline:34242467 doi:10.1113/EP089309
39. Kim C, McGee S, Khuntia S, Elnour A, Johnson-Clarke F, Mangla A, et al. Analysis of the Behaviour of Immunoglobulin G Antibodies in Children and Adults Convalescing From Severe Acute Respiratory Syndrome-Coronavirus-2 Infection. Front Pediatr. 2021;9:671831. Medline:34485190 doi:10.3389/fped.2021.671831
40. Nikolopoulou GB, Maltezou HC. COVID-19 in children: where do we stand? Arch Med Res. 2021. Epub ahead of print. Medline:33986150 doi:10.1542/peds.2021-051462
41. Havers FP, Whitaker M, Self JL, Chai SJ, Kirley PD, Alden NB, et al; COVID-NET Surveillance Team. Hospitalization of Adolescents Aged 12-17 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1, 2020-April 24, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:744-8. Medline:34455523 doi:10.15585/mmwr.mm7023e1
42. Nikolopoulou GB, Maltezou HC. COVID-19 in children: where do we stand? Arch Med Res. 2021. Epub ahead of print. Medline:34311990 doi:10.1016/j.arcmed.2021.07.002
43. Shah K, Upadhyaya M, Kandre Y, Pandya A, Saraf V, Saxena D, et al. Epidemiological, clinical and biomarker profile of pediatric patients infected with COVID-19. QJM. 2021;114:476-95. Medline:34293142 doi:10.1093/qjmed/hcab206
44. Zar HJ, Duwa J, Fischer GB, Castro-Rodriguez JA. Challenges of COVID-19 in children in low- and middle-income countries. Paediatr Respir Rev. 2020;35:70-4. Medline:32654834 doi:10.1016/j.prrv.2020.06.016
45. Gurugubelli KR, Bhat BV. Coronavirus Disease 2019 Infection among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study. Clin Infect Dis. 2021;9:323-32. Medline:34397776 doi:10.1097/INF.0000000000003227
46. Boey L, Roelants M, Merckx J, Hens N, Desombere I, Dyusburgh E, et al. Age-dependent seroprevalence of SARS-CoV-2 antibodies in school-aged children from areas with low and high community transmission. Eur J Pediatr. 2021. Epub ahead of print. Medline:34455523 doi:10.1007/s00431-021-04222-9
47. Márquez-González H, López-Martínez B, Parra-Ortega I, de la Rosa-Zamboni D, Salazar-García M, Oliver-López V, et al. Analysis of the Behaviour of Immunoglobulin G Antibodies in Children and Adults Convalescing From Severe Acute Respiratory Syndrome-Coronavirus-2 Infection. Front Pediatr. 2021;9:671831. Medline:34485190 doi:10.3389/fped.2021.671831
48. Delahoy MJ, Ujamaa D, Whitaker M, O’Halloran A, Anglin O, Burns E, et al; COVID-NET Surveillance Team. COVID-NET Surveillance Team. Hospitalizations Associated with COVID-19 Among Children and Adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1235-60. Medline:34499627 doi:10.15585/mmwr.mm7036e2
49. Siegel DA, Reses HE, Cool AJ, Shapiro CN, Hsu J, Boehner TK, et al. Trends in COVID-19 Cases, Emergency Department Visits, and Hospital Admissions Among Children and Adolescents Aged 0-17 Years - United States, August 2020-August 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1249-54. Medline:34499628 doi:10.15585/mmwr.mm7036e1
51 Guimarães R, Villela DAM, Xavier DR, Saldanha R, Barcellos C, de Freitas CM, et al. Increasing impact of COVID-19 on young adults: evidence from hospitalisations in Brazil. Public Health. 2021;198:297-300. Medline:34507135 doi:10.1016/j.puhe.2021.08.002

52 Keuring MW, Grobben M, de Groen AC, Berman-de Jong EP, Bijlsma MW, Cohen S, et al. Saliva SARS-CoV-2 Antibody Prevalence in Children. Microbiol Spectr. 2021;9.e0073121. Medline:34523985 doi:10.1128/Spectrum.00731-21

53 Galindo R, Chow H, Rongkvivit C. COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin North Am. 2021;68:961-76. Medline:34538306 doi:10.1016/j.pcl.2021.05.004

54 Blanchard-Rohner G, Didierlaurent A, Tilmanne A, Smeerstra P, Marchant A. Pediatric COVID-19: Immunopathogenesis, Transmission and Prevention. Vaccines (Basel). 2021;9.1002. Medline:34579240 doi:10.3390/vaccines9091002

55 Drouin O, Hepburn CM, Farrar DS, Baerg K, Chan K, Cyr C, et al; Canadian Paediatric Surveillance Program COVID-19 Study Team. Characteristics of children admitted to hospital with acute SARS-CoV-2 infection in Canada in 2020. CMAJ. 2021;193:E1483-93. Medline:34580141 doi:10.1503/cmaj.210055

56 Vono M, Huttner A, Lemeille S, Martinez-Murillo P, Meyer B, Baggio S, et al. Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity. Cell Rep. 2021;37:109773. Medline:34587479 doi:10.1016/j.celrep.2021.109773

57 Antoon JW, Grijalva CG, Thurc C, Richardson T, Spaulding AB, Teufel RJ II, et al. Factors Associated With COVID-19 Disease Severity in US Children and Adolescents. J Hosp Med. 2021;16:603-10. Medline:34613896 doi:10.12788/jhm.3689

58 Dawood FS, Ponczukin CA, Veggulla V,スタンダード FR, Duque J, Rolles MA, et al. Incidence Rates, Household Infection Risk, and Clinical Characteristics of SARS-CoV-2 Infection Among Children and Adults in Utah and New York City, New York. JAMA Pediatr. 2021. Epub ahead of print. Medline:34632377 doi:10.1001/jamapediatrics.2021.4217

59 Howard-Jones AR, Bowen AC, Danchin M, Koirala A, Sharma K, Yeoh DK, et al. COVID-19 in children: I. Epidemiology, prevention and indirect impacts. J Paediatric Child Health. 2021. Epub ahead of print. Medline:34643307 doi:10.1111/jpc.15791

60 Laub O, Leipold G, Toncheva AA, Peterhoff D, Einhauser S, Neckermann P, et al. Corona Virus Antibodies in Children from Bavaria (CoKiBa) Study Group. Symptoms, SARS-CoV-2 Antibodies, and Neutralization Capacity in a Cross-Sectional-Population of German Children. Front Pediatr. 2021;9.678937. Medline:34671582 doi:10.3389/fped.2021.678937

61 Howard-Jones AR, Burgner DP, Crawford NW, Goeman E, Gray PE, Hsu P, et al. COVID-19 in children: II. Pathogenesis, disease spectrum and management. J Paediatric Child Health. 2021. Epub ahead of print. Medline:34694337 doi:10.1111/jpc.15811

62 Levorson RE, Christian E, Hunter B, Sayal J, Sun J, Bruce SA, et al. A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States. PLoS One. 2021;16:e0259823. Medline:34748615 doi:10.1371/journal.pone.0259823

63 Wurzel D, McMinn A, Hoq M, Blyth CC, Burgner D, Tosif S, et al. Prospective characterisation of SARS-CoV-2 infections among children presenting to tertiary paediatric hospitals across Australia in 2020: a national cohort study. BMJ. 2021;11:e054510. Medline:34730151 doi:10.1136/bmjopen-2021-054510

64 Smith C, Odd D, Harwood R, Ward J, Linney M, Clark M, et al. Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Lancet. 2021. Epub ahead of print. Medline:34769489 doi:10.1016/s41591-021-01578-1

65 Zinserling VA, Bornstein SR, Narkevich TA, Sukhanova VY, Svenova NY, Vashukova MA, et al. Stillborn child with diffuse SARS-CoV-2 viral infection of multiple organs. IDCases. 2021;26:e01328. Medline:34777995 doi:10.1016/j.idcr.2021.e01328

66 Chao JY, Sugarman A, Kimura A, Flamer S, Jing TT, Fernandes DM, et al. Factors associated with hospitalization in children and adolescents with SARS-CoV-2 infection. Clin Pediatr (Philad). 2021. Epub ahead of print. Medline:34780028 doi:10.1177/00099228211059883

67 Naleway AL, Groom HC, Crawford PM, Salas SB, Henningter ML, Donald JL, et al. Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status - Oregon and Washington, July 4-September 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1608-12. Medline:34793417 doi:10.15585/mmwr.mmr.7046a6

68 Akashi T, Kishimoto S, Katori Y, Sugawara N, Igarashi K, Fujita M, et al. COVID-19 Transmission at Schools in Japan. Tohoku J Exp Med. 2021;255:239-46. Medline:34803121 doi:10.1620/tjem.255.239

69 Zinszer K, McKinnon B, Bourque N, Pierce L, Sauzier A, Otis A, et al. Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada. JMAM New Open. 2021.e42135975. Medline:34812845 doi:10.1001/jamanetworkopen.2021.35975

70 Uka A, Baetdcher M, Bernhard-Strommann S, Fougère Y, Moussaoui D, Kottanattu L, et al. Factors associated with hospital and intensive care admission in paediatric SARS-CoV-2 infection: a prospective nationwide observational cohort study. Eur J Pediatr. 2021. Epub ahead of print. Medline:34845526 doi:10.1007/s00431-021-04276-9

71 Merck J, Lahrecque JA, Kaufman JS. Transmission of SARS-CoV-2 by Children. Dtsch Arztebl Int. 2020;117:553-60. Medline:32703983

72 Baggio S, L’Huillier AG, Verly S, Bellon M, Wagner N, Rohr M, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Upper Respiratory Tract of Children and Adults With Early Acute Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2021;73:148-50. Medline:32761228 doi:10.1093/cid/ciaa1157

73 Desmet S, Ekinci E, Wouters I, Decru B, Beuselinck K, Malhotra-Kumar S, et al. No SARS-CoV-2 carriage observed in children attending daycare centers during the initial weeks of the epidemic in Belgium. J Med Virol. 2021;93:1828-31. Medline:33230857 doi:10.1002/jmv.26689

74 Lewis SJ, Munro APS, Smith GD, Pollock AM. Closing schools is not evidence based and harms children. BMJ. 2021,372. Medline:33622685 doi:10.1136/bmj.n521
REFERENCES

1. Munro A, Bowen AC, Cevik M. COVID-19, children and schools: overlooked and at risk. Med J Aust. 2021;214:188-188. e1. Medline:33641173 doi:10.5694/mja2.50933

2. Rostad CA, Kamidani S, Anderson EJ. Implications of SARS-CoV-2 Viral Load in Children: Getting Back to School and Normal. JAMA Pediatr. 2021;175:e212022. Medline:34115097 doi:10.1001/jamapediatrics.2021.2022

3. Willyard C. COVID and schools: the evidence for reopening safely. Nature. 2021;595:164-7. Medline:34234340 doi:10.1038/d41586-021-01826-x

4. Yonker LM, Boucau J, Regan J, Choudhary MC, Burns MD, Young N, et al. Virologic features of SARS-CoV-2 infection in children. medRxiv [Preprint]. 2021 Aug 17;2021.05.30.21258086. Update in: J Infect Dis. 2021 Oct 14; PMID: 34124714; PMCID: PMC8193793. doi:10.1101/2021.05.30.21258086

5. Cotugno N, Ruggiero A, Pascucci GR, Bonfante F, Petarra MR, Pigli C, et al. Virological and immunological features of SARS-CoV-2 infected children with distinct symptomatology. Pediatr Allergy Immunol. 2021;32:1833-42. Medline:34174102 doi:10.1111/pai.13985

6. Chung E, Chow EJ, Wilcox NC, Burstein R, Brandstetter E, Han PD, et al. Comparison of Symptoms and RNA Levels in Children and Adults With SARS-CoV-2 Infection in the Community Setting. JAMA Pediatr. 2021;175:e212025. Medline:34115094 doi:10.1001/jamapediatrics.2021.2025

7. Bartsch YC, Wang C, Zohar T, Fischinger S, Atyeo C, Burke JS, et al. Humoral signatures of protective and pathologic SARS-CoV-2 infection in children. Nat Med. 2021;27:454-62. Medline:33589825 doi:10.1038/s41591-021-01263-3

8. Yonker LM, Boucau J, Regan J, Choudhary MC, Burns MD, Young N, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. J Infect Dis. 2021. Epub ahead of print. Medline:34647601 doi:10.1093/infdis/jiab309

9. Petarra MR, Bonfante F, Costenaro P, Cantarutti A, Carmona F, Ruffoni E, et al. Asymptomatic and Mild SARS-CoV-2 Infections Ellicit Lower Immune Activation and Higher Specific Neutralizing Antibodies in Children Than in Adults. Front Immunol. 2021;12.741796. Medline:34692335 doi:10.3389/fimmu.2021.741796

10. Keuning MW, Grobben M, de Groen AC, Berman-de Jong EP, Bijlsma MW, Cohen S, et al. Saliva SARS-CoV-2 Antibody Prevalence in Children. Microbiol Spectr. 2021;9.e0073121. Medline:34523895 doi:10.1128/spectrum.00731-21

11. Aleyinka A, Bailey K, Pierre L, Kondamudi N. COVID-19 infection: Pediatric perspectives. J Am Coll Emerg Physicians Open. 2021;2.e12375. Medline:33554209

12. Mehrabani S. COVID-19 Infection and Children: A Comprehensive Review. Int J Prev Med. 2020;11:157. Medline:33312466 doi:10.4103/ijpvm.IJPVM_277_20

13. Peng D, Zhang J, Ji Y, Pan D. Risk factors for redetectable positivity in recovered children. Pediatr Pulmonol. 2020;55:3602-9. Medline:33049115 doi:10.1002/ppul.25116

14. Selva KJ, van de Sandt CE, Lemke MM, Lee CY, Shoffner SK, Chua BY, et al. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat Commun. 2021;12.2037. Medline:33795692 doi:10.1038/s41467-021-022236-7

15. Rubin D, Coffin S. On the Value of COVID-19 Testing for Children Beyond the Spring of 2021. JAMA Netw Open. 2021;4:e217890. Medline:33890994 doi:10.1001/jamanetworkopen.2021.7850

16. Snape MD, Viner RM. COVID-19 in children and young people. Science. 2020;370:286-8. Medline:32958582 doi:10.1126/science.abd6165

17. Felsenstein S, Hedrich CM. SARS-CoV-2 infections in children and young people. Clm Immunol. 2020;220:108588. Medline:32903851 doi:10.1016/j.clim.2020.108588

18. Nasrghandi A, Saffarpour R, Allameh SF. Exploring the causes of mild COVID-19 involvement in pediatric patients. New Microbes New Infect. 2020;37:100741. Medline:32837728 doi:10.1016/j.nmni.2020.100741

19. Sinaei R, Pezeshki S, Parvaresh S, Sinaei R. Why COVID-19 is less frequent and severe in children: a narrative review. World J Microbes New Infect. 2020;37:e217850. Medline:33890994 doi:10.1001/jamanetworkopen.2021.7850

20. Felsenstein S, Hedrich CM. SARS-CoV-2 infections in children and young people. Clm Immunol. 2020;220:108588. Medline:32903851 doi:10.1016/j.clim.2020.108588

21. Warner S, Richter A, Stamataki Z, Kelly D. Understanding COVID-19: are children the key? BMJ Paediatr Open. 2021;5:76. Medline:33630212 doi:10.1136/archdischld-2020-320338

22. Boechat JL, Wandalsen GF, Kuschnir FC, Delgado L. COVID-19 and Pediatric Asthma: Clinical and Management Challenges. Int J Environ Res Public Health. 2021;18:1093. Medline:33530624 doi:10.3390/ijerph18031093

23. Warner S, Richter A, Stamataki Z, Kelly D. Understanding COVID-19: are children the key? BMJ Paediatr Open. 2021;5:e001063. Medline:34192201 doi:10.1136/bmjpo-2021-001063

24. Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children (Basel). 2020;7:69. Medline:32630212 doi:10.3390/children7070069

25. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20:e276-88. Medline:32818434 doi:10.1016/S1473-3099(20)30365-1

26. Rostad CA, Chabroudi A, Mantus G, Lapp SA, Teherani M, Macoy L, et al. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). Pediatrics. 2020;146:e2020018242. Medline:32879033 doi:10.1542/peds.2020-018242

27. Rothan HA, Byaradely SN. The potential threat of multisystem inflammatory syndrome in children during the COVID-19 pandemic. Pediatr Allergy Immunol. 2021;32:17-22. Medline:32897642 doi:10.1111/pai.13361

28. Zeichner SL, Cruz AT. Multisystem Inflammatory Syndrome in Children and SARS-CoV-2 Serology. Pediatrics. 2020;146: e2020032888. Medline:32973121 doi:10.1542/peds.2020-032888
102 Grazioli S, Tavaglione F, Torriani G, Wagner N, Rohr M, L’Huillier AG, et al. Immunological Assessment of Pediatric Multisystem Inflammatory Syndrome Related to Coronavirus Disease 2019. J Pediatric Infect Dis Soc. 2021;10:706-13. Medline:33180935 doi:10.1093/jpids/piaa142

103 Rostad BS, Shah JH, Rostad CA, Jaggi P, Richer EJ, Linam LE, et al. Chest radiograph features of multisystem inflammatory syndrome in children (MIS-C) compared to pediatric COVID-19. Pediatr Radiol. 2021;51:231-8. Medline:33404786 doi:10.1007/s00247-020-09421-9

104 Fouraki A, Fougère Y, De Camaret C, Blanchard Rohner G, Grazioli S, Wagner N, et al. Case Report: Case Series of Children With Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Switzerland. Front Pediatr. 2021;8:594127. Medline:33469522 doi:10.3389/fped.2020.594127

105 Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Overcoming COVID-19 Investigators. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021;325:1074-87. Medline:33625505 doi:10.1001/jama.2021.2091

106 Vogel TP, Top KA, Karatzios C, Hilmers DC, Tapia LI, Moceri P, et al. Multisystem inflammatory syndrome in children and adults (MIS-CA): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021;39:3037-49. Medline:33640145 doi:10.1016/j.vaccine.2021.01.054

107 Perez-Toledo M, Faustini SE, Jossi SE, Shields AM, Marcial-Juarez E, Kathinthaminathan HK, et al. SARS-CoV-2-specific IgG1/IgG3 but not IgM in children with Pediatric Inflammatory Multi-System Syndrome. Pediatr Allergy Immunol. 2021;32:1125-9. Medline:33724541 doi:10.1111/pai.13504

108 Chen MR, Kuo HC, Lee YJ, Chi H, Li SC, Lee HC, et al. Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Pediatric Systemic Inflammatory Syndrome in Children. Front Immunol. 2021;12:632890. Medline:33733270 doi:10.3389/fimmu.2021.632890

109 Salzman MB, Huang CW, O’Brien CM, Castillo RD. Multisystem Inflammatory Syndrome after SARS-CoV-2 Infection and COVID-19 Vaccination. Emerg Infect Dis. 2021;27:3944-8. Medline:34034838 doi:10.3201/eid2707.210594

110 Hennon TR, Yu KOA, Fenque MD, Abdul-Aziz R, Chang AC, McGreavy MB, et al. COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; revisiting the Western New York approach as the pandemic evolves. Prog Pediatr Cardiol. 2021;62:101407. Medline:34121829 doi:10.1016/j.ppedcard.2021.101407

111 Schlapbach LJ, Andre MC, Grazioli S, Schobi N, Ritz N, Aebi C, et al. PIMS-TS working group of the Interest Group for Pediatric Neonatal Intensive Care (IGPNI) of the Swiss Society of Intensive Care and the Pediatric Infectious Diseases Group Switzerland (PIG5). Best Practice Recommendations for the Diagnosis and Management of Children with Multisystem Inflammatory Syndrome Temporarily Associated With SARS-CoV-2 (PIMS-TS, Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland. Front Pediatr. 2021;9:667507. Medline:34123970 doi:10.3389/fped.2021.667507

112 Castagnola E, Mariangiola M, Sticchi C, Sticchi L, Spiazzi R, Gaio E, et al. Impact of COVID-19 on paediatics. A good reason to vaccinate children against SARS-CoV-2. Acta Paediatr. 2022. Epub ahead of print. Medline:34432905 doi:10.1111/apa.16081

113 Vella LA, Rowley AH. Current Insights Into the Pathophysiology of Multisystem Inflammatory Syndrome in Children. Curr Pediatr Rep. 2021. Epub ahead of print. Medline:34692237 doi:10.1007/s40124-021-00257-6

114 Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. J Pediatric Infect Dis Soc. 2020;9:701-15. Medline:32318706 doi:10.1093/jpids/piaa045

115 Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. J Pediatric Infect Dis Soc. 2021;34:34-48. Medline:32918548 doi:10.1093/jpids/piaa115

116 Wolf J, Abzug MJ, Wattier RL, Sue PK, Vora SB, Zachariah P, et al. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children. Pediatr Infect Dis Soc. 2021;10:629-34. Medline:33388760 doi:10.1093/pids/piaa175

117 Alcindor ML, Alcindor F Richard KE, Ajay G, Denis AM, Dickson DM, et al. COVID-19 Management in Pediatrics. J Nurse Pract. 2021;17:528-35. Medline:33723483 doi:10.1016/j.nurpra.2021.02.010

118 Blumenthal JA, Duvall MG. Invasive and noninvasive ventilation strategies for acute respiratory failure in children with coronavirus disease 2019. Curr Opin Pediatr. 2021;33:311-8. Medline:33851935 doi:10.1097/MOP.0000000000001021

119 Levy ER, Blumenthal J, Chiotos K. Coronavirus disease 2019 in children. Curr Opin Pediatr. 2021;34:500-9. Medline:34261902 doi:10.1097/MOP.0000000000001702

120 Haji Esmaeil Memar E, Pourakbari B, Gorgi M, Sharifzadeh Ekbatani M, Navacian A, Khodabandeh M, et al. COVID-19 and congenital heart disease: a case series of nine children. World J Pediatr. 2021;17:71-8. Medline:33387256 doi:10.1007/s12519-020-00397-7

121 Shaunak M, Patel R, Driessens C, Mills L, Leahy A, Gheshemite D, et al. ImmunoCOVID19 study group. COVID-19 symptoms surveillance in immunocompromised children and young people in the UK: a prospective observational cohort study. BMJ Open. 2021;11:e048899. Medline:33373749 doi:10.1136/bmjopen-2020-048899

122 Rouger-Gaudichon J, Bertrand Y, Boissel N, Brethon B, Ducassou S, Gandemer V, et al. Leukemia Committee of the SFCE. COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE). Bull Cancer. 2021;108:490-500. Medline:33781351 doi:10.1016/j.bulcan.2021.02.004

123 L’Huillier AG, Ardura MI, Chaudhuri A, Danziger-Izakov L, Dulek D, Green M, et al. COVID-19 vaccination in pediatric solid organ transplant recipients—Current state and future directions. Pediatr Transplant. 2021;25:e14031. Medline:34076928 doi:10.1111/petr.14031

www.jogh.org • doi: 10.7189/jogh.11.01010
REFERENCES

124 Nigro O, Sironi G, Bergamaschi L, Gattuso G, Puma N, Livellara V, et al. SARS-CoV-2 vaccination for adolescents and young adult patients treated at a specialist pediatric oncology unit. Pediatr Blood Cancer. 2021;68:e29240. Medline:34264546 doi:10.1002/pbc.29240

125 Tinkler SC, Cogswell ME, Peacock G, Ryerson AB. Important Considerations for COVID-19 Vaccination of Children With Developmental Disabilities. Pediatrics. 2021;148:e2021053190. Medline:34272340 doi:10.1542/peds.2021-053190

126 Revon-Riviere G, Ninove L, Min V, Rome A, Coze C, Verschuur A, et al. The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. Eur J Cancer. 2021;154:30-4. Medline:34233234 doi:10.1016/j.ejca.2021.06.002

127 Haskin O, Ashkenazi-Hoffnung L, Ziv N, Borovitz Y, Dagan A, Levi S, et al. Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients. Transplantation. 2021;105:e226-33. Medline:34381004 doi:10.1097/TP.0000000000003922

128 Moeller KE, Meeks M, Reynolds J, Douglass M. Implementation and Outcomes of COVID-19 Vaccinations at a Child and Adolescent Psychiatric Hospital. J Am Acad Child Adolesc Psychiatry. 2021;60:1332-4. Medline:34481918 doi:10.1016/j.jaac.2021.08.018

129 Luxi N, Giovannazzi A, Capuano A, Crisafulli S, Cutroneo PM, Fantini MP, et al. Ilmiovaccino COVID19 collaborating group. COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Saf. 2021. Epub ahead of print. Medline:34739716 doi:10.1007/s40264-021-01131-6

130 Aiano F, Campbell C, Saliba V, Ramsay ME, Ladhani SN. COVID-19 vaccine given to children with comorbidities in England, December 2020-June 2021. Arch Dis Child. 2021. Epub ahead of print. Medline:34740880 doi:10.1136/archdischild-2021-323162

131 Emes D, Huls A, Baumer N, Dienssen M, Puri S, Russell L, et al. Trisomy Research Society Covid-Initiative Study Group. COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey. J Clin Med. 2021;10:5125. Medline:34786945 doi:10.3390/jcm10215125

132 Choi K, Becerra-Culqui T, Bhakta B, Bruxvoort K, Coleman KJ. Parent intentions to vaccinate children with autism spectrum disorder against COVID-19. J Pediatr Nurs. 2021. Epub ahead of print. Medline:34836713 doi:10.1016/j.pedn.2021.11.019

133 Wimberly CE, Towry L, Davis E, Johnston EE, Walsh KM. SARS-CoV-2 vaccine acceptability among caregivers of childhood cancer survivors. Pediatr Blood Cancer. 2021. Epub ahead of print. Medline:34786824 doi:10.1002/pbc.29443

134 Shire ZJ, Reicherz F, Lawrence S, Sudan H, Golding L, Majdoubi A, et al. Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy. Gut. 2021. Epub ahead of print. PMID: 34815272. Medline:34815272 doi:10.1136/gutjnl-2021-326196

135 Dimopoulou D, Vartzelis G, Dasoula F, Tsolia M, Maritsi D. Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis. 2021. Epub ahead of print. PMID: 34844930. Medline:34844930 doi:10.1136/annrheumdis-2021-221607

Correspondence to:
Professor Igor Rudan, FRSE
Centre for Global Health
The Usher Institute, The University of Edinburgh
30 West Richmond Street
Edinburgh, EH8 9DX,
Igor.Rudan@ed.ac.uk